TRUSTID LIMITED

Company number 05953015 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Assessment: TRUSTID LIMITED (05953015)

Patient profile: Software company (identity verification / Right to Work / AML-KYC checks), incorporated 2006, wholly-owned subsidiary of Citation Holdings Limited. Accounts are filleted (no P&L filed), so profitability is inferred from movements in retained earnings.


1. Financial Health Score: D+ — Weak, but stabilising under group life support

On a standalone basis, this balance sheet is in poor health: the company is balance-sheet insolvent with net liabilities of £2.53m, negative working capital of £2.70m, and accumulated losses of £6.14m that have consumed all £3.5m of injected share capital and premium. However, the grade is held above E/F by three mitigating factors: losses are narrowing sharply (from ~£1.45m in 2023 to ~£540k in 2024), the cash position is improving, and the company benefits from the backing of a substantial parent group. Think of a patient with a serious chronic condition whose vital signs are finally moving in the right direction — but who remains dependent on ongoing external support.


2. Key Vital Signs

Vital Sign FY2024 FY2023 Clinical Reading
Net assets / (liabilities) (£2,534,946) (£2,069,150) Negative and deteriorating — the core chronic symptom
Net current assets (working capital) (£2,696,905) (£2,229,553) Severely negative; healthy is positive
Current ratio 0.38 0.42 Critical — healthy pulse is 1.5+; only 38p of short-term assets per £1 of short-term debt
Cash at bank £782,197 £474,925 Improving (+65%) — a genuinely healthy sign
Trade debtors £876,291 £1,125,946 Down 22% — better collection or lower billings
Creditors due < 1 year £4,355,393 £3,830,424 Large and rising — almost certainly group/intercompany funding
Retained earnings (accumulated losses) (£6,137,068) (£5,596,644) Implies a FY2024 loss of ~£540k
Implied annual loss ~£540k ~£1,450k Bleeding has slowed dramatically

Note: the "shareholders' funds" figures in the financial history feed correspond to retained earnings per the filed balance sheet; true shareholders' funds equal net assets (–£2.53m in 2024).


3. Symptoms Analysis

Chronic symptoms (long-standing): - Persistent balance-sheet insolvency. Net assets have been negative in 8 of the last 10 years, with only brief remissions (2015: +£282k; 2018: +£24k). The deficit has deepened every year since 2021. - Capital depletion. Shareholders have injected ~£3.5m (share capital + premium); cumulative losses of £6.1m have consumed all of it plus £2.5m more. - Structural dependence on short-term creditor funding. £4.36m falls due within one year against £1.66m of current assets. For a wholly-owned subsidiary, this is typically parent-group funding — effectively the patient is on a financial drip feed from Citation Holdings.

Positive symptoms (signs of recovery): - Loss trajectory is improving: ~£314k (2021) → ~£1.0m (2022) → ~£1.45m (2023) → ~£540k (2024). The 2022–23 spike looks like an investment/restructuring phase now being brought under control. - Cash is at its second-highest level in a decade and rose £307k in 2024 despite the loss — indicating working capital is being managed (debtors down £250k) and creditors are absorbing the deficit. - Small equity injection in 2024 (~£61k of new share premium) shows the parent continues to put money in. - Clean compliance record: filings current, no overdue accounts, no director disqualifications, active for nearly 20 years in a growing regulated market (certified IDSP for digital Right to Work checks).


4. Diagnosis

Chronic capital deficiency with acute working-capital shortfall, currently stabilising on group support.

This is a company that has been loss-making for most of a decade and is technically insolvent on a balance-sheet basis. It survives because its parent funds the gap between its £4.36m of current liabilities and its £1.66m of current assets. The directors' going-concern statement confirms reliance on projected performance and solvency support. The business is not in acute distress — cash is adequate and losses are narrowing — but it could not meet its obligations unaided if parental support were withdrawn. The equity deficit is so deep that even a return to profit would take many years to repair it organically.


5. Prognosis

Guarded but improving. If the current trajectory continues (the loss roughly halved in 2024), breakeven within 1–2 years is plausible, aided by favourable market tailwinds as digital identity checking becomes embedded in UK hiring, renting, and AML compliance. However, the £2.5m equity hole will not heal through trading alone within any reasonable timeframe — a recapitalisation is the realistic cure. The single greatest risk factor is a change in parent-group strategy (e.g., disposal of the subsidiary or withdrawal of intercompany forbearance).


6. Recommendations

  1. Formalise the life support. Ensure a written parent letter of support/comfort underpins the going-concern basis, and document quarterly going-concern reviews — essential protection for directors against wrongful-trading exposure while net liabilities persist.
  2. Recapitalise the balance sheet. Convert intercompany debt to equity, or secure a substantial equity injection, to restore positive net assets rather than letting the deficit compound.
  3. Run 13-week rolling cash-flow forecasts. With a current ratio of 0.38, liquidity timing — not just profitability — is the immediate survival metric.
  4. Dissect the £4.36m creditor balance. Separate group funding from trade creditors and accruals; extend terms or reschedule where any non-group amounts sit.
  5. Maintain debtor discipline. The £250k reduction in debtors helped cash; keep monitoring days-sales-outstanding as revenue (hopefully) grows.
  6. Set a milestone-based path to profitability with monthly board review, given the encouraging ~63% reduction in annual losses.
  7. Scenario-plan for group events. Model the impact of a parent sale, restructuring, or withdrawal of support, and ensure any audit-exemption parental guarantee (if relied upon) is properly filed and current.

Perspective: Financial Health Diagnostician · Model: kimi-k3 · Generated 26 October 2026